Table 3:
Risk factors | CIMT (μm) | IM-GSM | ||||
---|---|---|---|---|---|---|
R2=0.21 | R2=0.26 | |||||
β-estimate | (SE) | p-value | β-estimate | (SE) | p-value | |
Age, years | 4.65 | (0.56) | <.0001 | −0.226 | (0.06) | 0.0001 |
Race (%) | ||||||
White non-Hispanic | ref | ref | ||||
Black non-Hispanic | 27.78 | (13.54) | 0.04 | −1.715 | (1.437) | 0.23 |
Hispanic | −20.99 | (11.31) | 0.06 | −2.802 | (1.197) | 0.02 |
Asian | −3.831 | (14.13) | 0.79 | −2.690 | (1.461) | 0.07 |
Body mass index, kg/m2 | 2.95 | 1(.109) | 0.008 | −0.815 | (0.116) | <.0001 |
Physical activity, MET hours/week | 0.037 | (0.018) | 0.049 | |||
LDL-cholesterol, mg/dl | 0.24 | (0.12) | 0.05 | −0.026 | (0.013) | 0.04 |
HDL-cholesterol, mg/dl | −0.25 | (0.24) | 0.30 | 0.015 | 0.029) | 0.59 |
Triglycerides, mg/dl | −0.005 | 0.009 | 0.60 | |||
Systolic blood pressure, mmHg | 1.70 | (0.32) | <.0001 | −0.076 | 0.034 | 0.02 |
†Diastolic blood pressure, mmHg | 1.17 | (0.58) | 0.04 | −0.075 | (0.06) | 0.19 |
‡Antihypertensive medication use | 0.82 | (9.59) | 0.93 | −1.78 | (0.10) | 0.07 |
Glucose, mg/dl | −0.001 | (0.39) | 0.90 | −0.076 | (0.04) | 0.06 |
±Leptin, ng/ml | −0.11 | (0.29) | 0.70 | −0.099 | (0.03) | 0.002 |
Adiponectin, μg/ml | 0.049 | (0.06) | 0.44 | |||
Ghrelin, pg/ml | −0.0003 | (0.001) | 0.76 | |||
IL-6, pg/ml | 5.72 | (3.12) | 0.07 | −0.59 | (0.32) | 0.07 |
ICAM-1, ng/ml | 0.02 | (0.06) | 0.68 | −0.0004 | (0.006) | 0.95 |
E-selectin, ng/ml | −0.075 | (0.04) | 0.08 |
Risk factors significantly (p-value<0.05) associated in the univariate analysis were included in the multivariate model for each outcome
Results from separate model replacing SBP with DBP, R2 = 0.26 for IM-GSM, R2 = 0.18 for CIMT model
Results from separate model not including SBP and DBP, R2 = 0.20 for IM-GSM, R2 = 0.18 for CIMT model
Results from separate model not including BMI, R2 = 0.20 for IM-GSM, R2 = 0.20 for CIMT model